STRIASCAN

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Poland, United Kingdom

Active ingredients

The drug STRIASCAN contains one active pharmaceutical ingredient (API):

1 Ioflupane ¹²³I UNII 3MM99T8R5Q - IOFLUPANE I-123

Ioflupane ¹²³I is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Read about Ioflupane ¹²³I

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
STRIASCAN Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
V09AB03	Iodine ioflupane (123I)	V Various → V09 Diagnostic radiopharmaceuticals → V09A Central nervous system → V09AB Iodine (123I) compounds
Discover more medicines within V09AB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1798690, 1798702
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1191372001
Country: FR	Base de données publique des médicaments	Identifier(s): 69037684
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 395659
Country: IT	Agenzia del Farmaco	Identifier(s): 048078012, 048078024
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1088129, 1088130
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100423230